Multiparametric magnetic resonance imaging-transrectal ultrasound fusion prostate biopsy: A prospective, single centre study.

Introduction: Transrectal rectal ultrasound (TRUS)-guided systematic biopsy is the gold standard for diagnosis of prostate cancer. However, systematic biopsy has high false-negative rate and often misses anteriorly located tumors. Magnetic resonance imaging (MRI)-TRUS fusion biopsy can potentially i...

Descripción completa

Detalles Bibliográficos
Publicado en:Indian Journal of Urology Vol. 33; no. 2; pp. 134 - 140
Autores principales: Bansal, Somendra, Gupta, Narmada P., Yadav, Rajiv, Khera, Rakesh, Ahlawat, Kulbir, Gautam, Dheeraj, Ahlawat, Rajesh, Gautam, Gagan
Formato: pictorial research tables/charts Journal Article
Publicado: Wolters Kluwer India Pvt Ltd Apr-Jun2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122250185&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 122250185
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09701591
        1KUG
      jtl: Indian Journal of Urology
      issn: 09701591
      maglogo: N
    pubinfo:
      dt: Apr-Jun2017
      vid: 33
      iid: 2
      pid: 16919
      pub: Wolters Kluwer India Pvt Ltd
    artinfo:
      ui:
        122250185
        122250185
        122250185
        10.4103/0970-1591.203414
        122250185
      ppf: 134
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Multiparametric magnetic resonance imaging-transrectal ultrasound fusion prostate biopsy: A prospective, single centre study.
      aug:
        au:
          Bansal, Somendra
          Gupta, Narmada P.
          Yadav, Rajiv
          Khera, Rakesh
          Ahlawat, Kulbir
          Gautam, Dheeraj
          Ahlawat, Rajesh
          Gautam, Gagan
        affil: Department of Urology, Kidney and Urology Institute, Medanta The Medicity, Gurgaon, India
      sug:
        subj:
          Prostate Pathology
          Magnetic Resonance Imaging
          Biopsy
          Prostate
          Ultrasonography
          Family History
          Data Analysis, Statistical
          Prospective Studies
          Confidence Intervals
          Descriptive Statistics
          Probability
          Scales
      ab: Introduction: Transrectal rectal ultrasound (TRUS)-guided systematic biopsy is the gold standard for diagnosis of prostate cancer. However, systematic biopsy has high false-negative rate and often misses anteriorly located tumors. Magnetic resonance imaging (MRI)-TRUS fusion biopsy can potentially improve cancer detection by better visualization and targeting of cancer focus. We evaluated the role of fusion biopsy in detection of prostate cancer and the association of prostate imaging reporting and data system (PI-RADS) score for predicting cancer risk and its aggression. Methods: Ninety-six consecutive men with suspected prostate cancer underwent MRI-TRUS fusion-targeted biopsy of suspicious lesions and standard 12 core biopsy from May 2014 to July 2015 in our institution. All patients underwent 3.0 T multiparametric MRI before biopsy. mp-MRI included T2W, DWI, DCE and MRS sequences to identify lesions suspicious for prostate cancer. Suspected lesions were scored according to PI-RADS scoring system. Comparison of cancer detection between standard 12 core biopsy and MRI-TRUS fusion biopsy was done. Detection of prostate cancer was primary end point of this study. Results: Mean age was 64.4 years and median prostate-specific antigen was 8.6 ng/ml. Prostate cancer was detected in 57 patients (59.3%). Of these 57 patients, 8 patients (14%) were detected by standard 12 core biopsy only, 7 patients (12.3%) with MRI-TRUS fusion biopsy only, and 42 patients (73.7%) by both techniques. Of the 7 patients, detected with MRI-TRUS fusion biopsy alone, 6 patients (85.7%) had Gleason ≥7 disease. Prostate cancer was detected on either standard 12 core biopsy or MRI-TRUS fusion biopsy in 0%, 42.8%, 74%, and 89.3% patients of suspicious lesions of highest PI-RADS score 2, 3, 4, and 5, respectively. Conclusions: MRI-TRUS fusion prostate biopsy improves cancer detection rate when combined with standard 12 cores biopsy and detects more intermediate or high-grade prostate cancer (Gleason ≥7). With increasing PI-RADS score, there is an increase chance of detection of cancer as well as its aggressiveness.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N